Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus
e.g., angiotensin-converting enzyme inhibitor(s) [ACEi], or angiotensin receptor blockers [ARB]), currently available treatments include sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and nonsteroidal mineralocorticoid receptor antagonists (ns-MRA), such as finerenone [5,6,7,8]
Protein also steadies blood sugar, which can help prevent nausea that comes from sugar fluctuations
Pure Betaine Anhydrous Trimethylglycine Research has shown that betaine anhydrous trimethylglycine can directly lower levels of homocysteine in the body, making it an effective supplement for those with an MTHFR mutation
Treatment duration critically influences post-discontinuation outcomes with 6-12 month courses creating durable structural improvements supporting ongoing enhanced collagen synthesis without continuous peptide presence, while 2-3 month treatments produce temporary stimulation requiring continuous or cyclical application for maintaining optimal results